Ozapic approved in India, Novo Nordisk Country Head says ‘very important’
As India struggles with an increase in lifestyle related diseases, the approval of ozmpic marks is more than just a new diabetes medicine; This indicates a change towards modernization of chronic disease care. Calling it a “very important step”, the Managing Director of Novo Nordisk India welcomed the decision as timely intervention.
Danish drug manufacturer Novo Nordisk is ready to launch ozmpic (semglutide) in India, a step that will benefit patients suffering from type 2 diabetes in the country, the head of India, Vikrant Shrotriya said in a special conversation with India today.
Ozmpic is once a week -long injectionable brand that was originally approved to manage type 2 diabetes, but was seen as the most demanding of drugs in view of its benefits in weight management.
Talking to India today, Shrotriya said, “With the expectation of a highly anticipated launch, Novo Nordisk will now fulfill its semaglutide portfolio in India, provide many remedies to meet the needs of a variety of patients- Oral semaglutide for diabetes, advanced objection management”
The Ozapic was first approved by the US FDA in 2017. The company has not yet given details of the cost of the drug. Earlier this year, it was approved to sell the drug vegovi for obesity management.
Novo Nordisk is ready to close its patent termination for semaglutide next year, which is expected to highlight a wave of general versions from major Indian drug manufacturers. “With our patent ending in 2026, so many players will enter the market. Competitive intensity can reduce the cost of self -drugs, at least, between the generics,” said Shtiya.
“We are not a company that only believes in its pricing part. We also strongly believe in connection with our patients. The availability of drug, trust and reliability is an important part of our business. The quality of drugs is of paramount importance,” he said.
Nova Nordisk said, “On the decision of the World Health Organization to add ozmpic to its list of essential drugs, it indicates” the relevance of the drug “.
“When it is excluded as a part of an essential drug, it just goes to show how much it brings for people with diabetes and obesity,” Shrotriya made it clear, saying what kind of hue and chrying semaglutide you sometimes hear about. It only takes away from it, the relevance of the drug is established. “This reflects confidence between regulators, doctors and health care providers.”
Weight loss drugs have found poor presses because reports that indicate side effects that are rapidly difficult for management.
India has a large population of type 2 diabetes patients. 101 million people are suffering from the disease and another 254 million (and count) suffer from obesity. The number has doubled in the last decade, causing weight management a serious matter.
“Obesity will remain an issue for the world. The journey of GLP-1 has started in India. It will have to reach far and wide in every corner of the country. Obesity is not just an urban India problem. The start of the ozemic is a welcome change, and I am sure it will help bring more formulas in the government body,” Sritia said.
Injectable semaglutides indicated for type 2 diabetes also reduces the risks of major adverse cardiovascular phenomena (mace) and chronic kidney disease, providing it as a well -round therapy for patients.
